Procedure and device for visual detection of the degree of fitness of an isolated blood sample for v

专利摘要:
Procedure and device for visual detection of the degree of fitness of an isolated blood sample for validation in clinical analysis. The present invention relates to a method for visually identifying the degree of suitability of an isolated blood sample for validation of its subsequent clinical analysis, taking into account the degree of hemolysis of the sample. This procedure includes the comparison of the sample plasma with a degraded, continuous scale, divided into seven stages that are distributed, with equal size, from 55º to 00º and from 00º to 351º, with 00º being the red color in the Chromatic circle of the double cone model. The invention also relates to said degraded scale and the device containing it, which can be made of different materials (paper, cardboard, cardboard-pen, plastic, metal). (Machine-translation by Google Translate, not legally binding)
公开号:ES2733148A1
申请号:ES201900050
申请日:2019-03-28
公开日:2019-11-27
发明作者:Soriano Ismael Ortuno；Castrillon Emilio Vargas；Lopez Leticia Carmen Simon；Mazarro María Dolores Ochoa；Bueno Sergio Luquero
申请人:Universidad Complutense de Madrid；
IPC主号:

专利说明:

[0001]
[0002] Procedure and device for visual detection of the degree of fitness of an isolated blood sample for validation in clinical analysis.
[0003]
[0004] Technical sector
[0005]
[0006] The present invention falls within the field of clinical analysis, more specifically, in the identification of the degree of hemolysis presented by isolated blood samples.
[0007]
[0008] Background of the invention
[0009]
[0010] Hemolysis is a phenomenon that can alter the results of analytical parameters.
[0011]
[0012] If cross-interference does not occur, generally, hemolysis increases the concentration of those determinations that have large concentrations at the intracellular level, and decreases those found at low concentrations.
[0013]
[0014] For example, Italo Moisés Saldaña collects a study of hemolysis interference on 25 biochemical constituents, of which 16 presented clinically significant interference (Saldaña, I.M. An Fac Med 2015; 76 (4): 377-384).
[0015]
[0016] To determine the degree of hemolysis of an isolated blood sample before proceeding with its clinical analysis, there are several methods. Fundamentally, methods based on the determination of the absorption spectrum of the sample are used by spectrophotometry, or visual methods. The most frequently used detection method is visual inspection, however, it is a method that, in general, is considered unreliable (Gómez Rioja, R., et al. Rev Lab Clin. 2009; 2 (4): 185-195). On the other hand, the methodologies that focus on the absorbances of the samples are more sensitive, but their application also has drawbacks: it implies additional costs and relatively extensive time requirements.
[0017] Several authors expose visual detection hemolysis scales through colorimetry or eppendorf tube photographs to show hemolysis intensity (Saldaña, IM An Fac Med 2015; 76 (4): 377-384; Plumhoff EA, et al. Mayo Medical Laboratories.
[0018] 2008; 33 (12): 1-8). Other authors are committed to the relevance of spectrophotometric techniques for the detection of hemolysis in isolated blood samples because they have greater precision (Appierto, V. et al. Bioanalysis. 2014; 6: 1215-1226). There are also comparative studies of other methods that are currently available, such as the detection of serum microRNAs (Shash, J.S. et al. PLoS ONE 2016; 11 (4) 1-12); In this work, the sensitivity of four different methods for the detection of low levels of hemolysis is analyzed and it is concluded that, of those analyzed, only the detection of microRNA and spectrophotometry are sufficiently sensitive.
[0019]
[0020] On the other hand, different cross-interference has been described in the determination of the hemolysis of a sample that could bias the identification of its intensity, both when spectrophotometric methods are used and when visual detection methods are used in the plasma, and, therefore, therefore, interfere with some analytical determinations. Cross-interference due to bilirubin and lipemia are especially important. Overheating lipemia and bilirubin underestimate the intensity of hemolysis and accuracy in determining blood constituents (Gómez Rioja, R., et al. Rev Lab Clin. 2009; 2 (4): 185-195). There is a non-linear relationship between the concentration of free plasma hemoglobin and the determination of total bilirubin, resulting in underestimation in small concentrations of hemolysis and vice versa (Saldaña, IM An Pac Med 2015; 76 (4): 377-384).
[0021] The International Organization for Standardization addresses the requirements of the quality system to be applied in the clinical laboratory (ISO 15189: 2012), focused on patient safety. Blood samples collected by venipuncture are the most common type of biological samples taken and sent to laboratories for analysis, for diagnostic and therapeutic monitoring. According to the guidelines of the World Health Organization, the laboratory should detect the presence of hemolysis in the isolated sample to analyze and assess whether it is a reason for rejection for any of the requested determinations (World Health Organization. Diagnostic Imaging and Laboratory Technology. (2002). Use of anticoagulants in diagnostic laboratory investigations. Geneva: World Health Organization. Available at: http://www.who.int/iris/handle/10665/65957).
[0022]
[0023] In the absence of a validated method that entails a low cost and short application time, it is still necessary to find a method of determining hemolysis in isolated blood samples, for clinical analysis, which is sufficiently fast, economical and reliable.
[0024]
[0025] Explanation of the invention.
[0026]
[0027] Procedure and device for visual detection of the degree of fitness of an isolated blood sample for validation in clinical analysis.
[0028]
[0029] One aspect of the present invention relates to a method for identifying the degree of fitness of an isolated blood sample for subsequent clinical analysis thereof. This procedure comprises a step in which the isolated blood sample to be analyzed is compared with a degraded scale according to the visual intensities of hemolysis in the plasma, which incorporates the entire range of color intensities from 55 ° to 00 ° and from 0 ° to 351 °, with 00 ° being the red color in the chromatic circle. These values reflect the amount of degrees of rotation around a double cone of colors from the color red (00 °).
[0030]
[0031] In this description, a degraded scale is understood as a colorimetry scale in which the intensity of the color increases progressively. To perform it, we used the tone in degrees, saturation and brightness in a double cone of colors and the HSL model (of the acronym Hue, Saturation and Lightness - hue, saturation, luminosity -), as well as the information of 277 samples of plasma.
[0032]
[0033] The double cone is constituted by two cones that settle on the same circular base and whose vertices are aligned with the center of the circle of said base. The upper and lower vertices correspond to brightness, white (100%) and black (0%) respectively; the distance to the axis with saturation, whose maximum intensity of each color is represented with 100% and the minimum intensity, which corresponds to a gray shadow, with 0%; and the angle corresponds to the color tone. The tone resides along the circular base of the double cone, forming a chromatic circle that is defined by three primary values through its position in the chromatic circle. The position of the three primary values has normalized, forming a triangle, in the following: primary red is 0 °, primary green is 120 ° and primary blue is 240 °, returning to red when we return to the origin of the circle at 360 °
[0034]
[0035] Three other secondary values (subtractive) are formed between the spaces of the first triangle, giving rise to a second triangle: yellow is located at 60 °, cyan at 180 ° and magenta at 300 °. Intermediate shades are generated by transitions between adjacent pairs of the positions of the primary and secondary (subtractive) colors, along the chromatic circle (orange, turquoise, etc.). Hence the position of the colors can be specified in degrees of angle (the full circle being 360 °).
[0036] The CMYK model (of the acronym Cyan, Magenta, Yellow and Key) is a subtractive color model that allows to represent a wide range of colors and has a good adaptation to industrial media. This model is based on the mixture of pigments of the cyan, magenta, yellow and black colors to create others and is the one that has been used to convert the colors obtained according to the HSL model to print values.
[0037]
[0038] Therefore, one aspect of the invention relates to a method for visually identifying the degree of fitness of an isolated blood sample for validation in clinical analyzes, by detecting the degree of hemolysis that the sample has undergone, which includes:
[0039]
[0040] - obtaining the plasma from the sample,
[0041]
[0042] - the comparison of the plasma color of the sample with a degraded color scale that includes the entire range of color intensities from 55 ° to 00 ° and from 00 ° to 351 °, with 00 ° being the red color in the chromatic circle of the double cone and in which said range of intensities is divided into 7 intervals of equal size that correspond to the following stages: stage 1: 55 ° -44 °; stage 2: 43 ° -38 °, stage 3: 37 ° -26 °; stage 4: 25 ° -16 °; stage 5: 15 ° -07 °; stage 6: 06 ° -01 °; stage 7: 00 ° -351 °, whose harmonization in saturation and brightness, respectively, are: stage 1: 35% - 44%, 99% - 89%; stage 2: 47% -50%, 90% -90%; stage 3: 50% -60%, 93% - 89%; stage 4: 68% -80%, 95% - 80%; stage 5: 71% -81%, 91% - 78%; stage 6: 68% -83%, 80% - 70%; stage 7: 82% -88%, 70% - 55% (Table 1),
[0043] - the assignment of the sample to a specific stage of the 7 stages of the degraded scale described in the previous step.
[0044]
[0045]
[0046]
[0047] Table 1. Definition of the stages of the degraded scale according to the mode or HSL
[0048]
[0049] Not all blood parameters are affected to the same extent by the hemolysis of the blood sample so the suitability of the sample must be taken into account in each of the determinations made with each sample. That is, each of the 7 stages of the degraded scale corresponds to a hemolysis intensity that implies the potential alteration of certain blood parameters whose number is increasing as the degree of hemolysis increases so that the number of alterations are cumulative to as the intensity of EDTA K2 / K3 plasma hemolysis increases in healthy adults. Therefore, the parameters that have been documented as potentially altered in blood samples with hemolysis are reflected below, depending on the intensity of hemolysis (mg / dL of deoxyhemoglobin), encompassed at each stage of the degraded scale.
[0050]
[0051] The data are represented as follows: potentially alterable parameters (stage number that encompasses all previous analytes); (number of other stadiums whose parameters are potentially affected).
[0052]
[0053] - Stage 1. Hydroxybutyrate Dehydrogenase (1)
[0054] - Stage 2. Aspartate aminotransferase (2); (one).
[0055]
[0056] - Stage 3. Total bilirubin (3); (two); (one).
[0057]
[0058] - Stage 4. Alanine Aminotransferase; pseodocholinesterase not inhibited and inhibited by dibucaine; Creatinine kinase; Ethanol; Gamma-Glutamyl Transferase; Iron; Ammonia
[0059] (4); (3); (two); (one).
[0060]
[0061] - Stage 5: Ferritin; Myoglobin; Phosphate (inorganic); Rheumatoid factors (5); (4); (3); (two); (one).
[0062]
[0063] - Stage 6: Alanine aminotransferase; C4 complement; Total cholesterol; C-reactive protein; Soluble transferrin receptor; Triglycerides; Valproic acid; Vancomycin
[0064] (6); (5); (4); (3); (two); (one).
[0065]
[0066] - Stage 7: alfal-acid glycoprotein; Alpha 1-Antripsin; Albumin; Apolipoprotein A-1; Apolipoprotein B; Antiestreptolysin O; Carbamazepine; Creatinine; Ultrasensitive C-reactive protein; Digoxin; Gentamicin; HK glucose; HDL cholesterol; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Lithium; Phenobarbital; Phenytoin; Salicylate; Theophylline; Total protein; Uric acid; Urea / BUN (7); (6); (5); (4); (3); (two); (one).
[0067]
[0068] In the event that the plasma of an isolated blood sample is subject to parameter analysis of the statements in the previous paragraph, its hemolysis intensity is visually evaluated and assigned to one of the 7 stages. Subsequently, it will be analyzed and the result of each parameter altered may be evaluated in combination with the stage to which it had been assigned. The stage number to which the sample is assigned must accompany the result of the parameters evaluated in the report, as an alert to the person responsible for validating the results. Thus, the results will be validated or rejected if, not being in a normal range, its corresponding hemolysis stage reaches a sufficient intensity to be compatible with a potential alteration of the results.
[0069]
[0070] In the event that the plasma of an isolated blood sample is subject to analysis of additional parameters to those stated in the previous paragraph, its hemolysis intensity is visually evaluated and assigned to one of the 7 stages. Subsequently, it will be analyzed and the result of each parameter altered may be evaluated in combination with the stage of the degraded scale. The number of the stadium with which the sample is identified must accompany the result of the sample in the report, as an alert to the person responsible for validating the results. Thus, the results will be validated or rejected if, not being in a normal range, its corresponding hemolysis stage reaches a sufficient intensity to be compatible with a potential alteration of the results of the analyzed parameters. In the same way, if the results of a parameter are not in the normal range and, for that sample, the hemolysis stage is not compatible with an expected alteration of these observed results, the physiological or pathological alteration of the patient is determined and, therefore, the need to repeat a sample is eliminated and costs are reduced.
[0071]
[0072] In the event that an isolated blood plasma sample is subject to analyte analysis of active drug principles, as in clinical trials, the intensity of hemolysis sufficient to trigger an alteration of the analyte facilitates the choice of final samples. analyze. In such a way that it avoids biases in the results of research in drugs and costs of the analysis of invalid samples.
[0073] As a result of the process of the invention, for an altered parameter compatible with hemolysis alteration according to the stage of the degraded scale to which it is assigned, the laboratory validation officer may issue the suspicion of an alteration of the plasma sample and not to a potential pathology of the patient, or, it can give a judgment of altered results not expected by a certain intensity of hemolysis in the sample. Therefore, by means of the procedure of the invention, the person responsible for the clinical analysis can decide whether or not to perform a second analysis of a second sample of isolated blood.
[0074]
[0075] In this procedure, a device can be used in which the degraded color scale preferably occupies a surface 210 mm high by 297 mm long, each stage corresponding to a size of 105 mm high by 41 mm wide , the set of the colors of the scale occupies 105 mm high by 287 long, with a margin of 52.5 mm at the top as at the bottom and 5 mm at the right as left in which the color is , preferably, matt white, and that can be manufactured in virtually any material: paper, cardboard, cardboard-pen, plastic, metal.
[0076]
[0077] A second aspect of the present invention relates to a degraded color scale to identify the degree of suitability of an isolated blood sample for validation in clinical analyzes, depending on the degree of hemolysis presented by said sample, which includes the entire range. of color intensities from 55 ° to 00 ° and from 00 ° to 351 °, with 00 ° being the red color in the chromatic circle of the double cone and in which said range of intensities is divided into 7 equal intervals size corresponding to the following stages: stage 1: 55 ° -44 °; stage 2: 43 ° -38 °; stage 3: 37 ° -26 °; stage 4: 25 ° -16 °; stage 5: 15 ° -07 °; stage 6: 06 ° -01 °; stage 7: 00 ° -351 °. Whose harmonization in saturation and brightness, respectively, are: stage 1: 35% - 44%, 99% - 89%; stage 2: 47% -50%, 90% -90%; stage 3: 50% -60%, 93% - 89%; stage 4: 68% -80%, 95% - 80%; stage 5: 71% -81%, 91% - 78%; stage 6: 68% -83%, 80% - 70%; stage 7: 82% -88%, 70% - 55%. This degraded scale can be used according to the procedure indicated in the previous paragraph.
[0078]
[0079] On the other hand, to use the degraded color scale to identify the degree of hemolysis of an isolated blood sample, a device can be developed in which the scale preferably occupies an area 210 mm high by 297 mm long, corresponding to each stage a size of 105 mm high by 41 mm wide, the set of colors of the scale occupies 105 mm high by 287 long, with a margin of 52.5 mm at the top as in the bottom and 5 mm on the right and left side where the color is preferably matte white. This device can be manufactured in virtually any material: paper, cardboard, cardboard-pen, plastic, metal.
[0080]
[0081] Brief description of the drawings
[0082]
[0083] To complement the description that is being made and in order to help a better understanding of the characteristics of the invention, figures are included as an integral part of said description, where, for illustrative and non-limiting purposes, the following has been represented:
[0084]
[0085] Figure 1. Degraded scale for visual hemolysis detection with indication of the values used for its elaboration.
[0086]
[0087] Figure 2. Example of degraded scale for visual detection of hemolysis, for use in the clinical analysis laboratory.
[0088]
[0089] Figure 3. Heterocedasticity between stages and relationship between absorbance and stages.
[0090] Preferred Embodiment of the Invention
[0091] The present invention is further illustrated by the following examples, which are not intended to be limiting in scope.
[0092] Example 1. Recruitment of samples.
[0093] Recruitment for the convenience of plasma samples in healthy adults, blind and single sample for visual detection of colorimetric hemolysis with standardized reference of absorbances. The sample selection criteria were as follows:
[0094] - Men and women.
[0095] - Age: between 18 and 55 years.
[0096] - Bilirubinemia in normal ranges. Monitoring through blood tests.
[0097] - Preprandial blood samples (*).
[0098] - No Smoking.
[0099] - Not have a diagnosed disease.
[0100] - Have blood parameters within normal ranges. Do not carry preprandials.
[0101] (*) Some postpandial samples may be included exceptionally if they are extracted as late as possible; The most common cause of lipemia is the recent intake of a meal high in saturated fats, so it will be necessary to apply a correction factor to these samples. Individuals who had total bilirubinemia between 0.2 and 1.2 mg / dl were included. Those who obtained a result of total bilirubinemia greater than 1.5 of the upper limit of normality and obtained a result of direct bilirubin equal to or greater than 35% of total bilirubin were excluded both for the elaboration of the scale and for its validation . The measurement was carried out by means of a safety blood test between 7 and 5 days before obtaining the sample for use in the elaboration and validation of this scale.
[0102] Individuals who had triglyceride values, fasting for 8-10 hours, less than 150 mg / dl were included. Those who reached said upper limits or results on an empty stomach were excluded both for the elaboration of the scale and for its validation. The measurement was performed by a safety blood test between 7 and 5 days before obtaining the sample for use on this scale. The samples used for the preparation and validation of the degraded scale were obtained on an empty stomach of at least 5 hours.
[0103] Example 2. Development of the scale.
[0104] An original scale of degraded colorimetry was developed according to the visual intensities of plasma hemolysis. The information of 277 plasma samples was used to construct a degraded scale, in which the intensity of the color increases progressively. For this, saturation, brightness and tone in degrees were used according to the HSL model and its correlation with CMYK codes.
[0105] As can be seen in Figure 1, the scale was designed including from 55 ° to 00 ° and from 00 ° to 351 °, with 00 ° being the red color in the chromatic circle of the double cone base. These values reflect the amount of degrees of rotation along the chromatic circle of the base of the double cone from the color red (00 °).
[0106]
[0107] The 277 samples were evaluated by spectrophotometry as indicated in Example 3. The color tones expressed in degrees and the results of the spectrophotometry are shown in Figure 1: the degrees at the top of the degraded scale and the hemolysis absorbances. at the bottom of the scale degrades. In both cases, the values used in the following examples for the study of concordance and in the statistical tests performed in the validation process of the hemolysis detection method in isolated blood samples have been marked in bold. From top to bottom, Figure 1 indicates:
[0108] - First line: adjusted color tone degrees that delimit each stage.
[0109]
[0110] - Second line: degrees of the color tone found in the experimental field work of the invention.
[0111]
[0112] - Third line: hemolysis absorbance limits found in the 277 samples used.
[0113] - Fourth line: arithmetic mean calculated from the hemolysis absorbance limits found in the 277 samples used (third line) at the ends of each stage.
[0114]
[0115] From the minimum intensity to the maximum absorbance intensity, the total of the scale was divided into 7 stages, that is, into 7 fragments of equal size representing 7 successive stages or stages of hemolysis that an isolated blood sample may present, from lower to higher hemolysis intensity.
[0116]
[0117] In this example, the scale was designed with a size of 105 mm high by 287 mm long, each stage corresponding to a size of 105 mm high by 41 mm wide. A device was made using 90 gram paper, in matt colors. As can be seen in Figure 1, the 7 stages in which the scale was divided were delimited by the intervals detailed in Table 2:
[0118]
[0119]
[0120]
[0121] Table 2. Intervals of the degraded scale in degrees of color tone and in dimensionless absorbance units in spectrophotometry.
[0122]
[0123] The scale was designed so that all stadiums occupy identical space in the total scale, which avoids visual distortion biases.
[0124]
[0125] Among the 7 stages, the clinical relevance has been considered to be between stage 1 and stage 2. It is considered that a blood sample with stage 1 hemolysis does not have a clinically relevant impact on most blood measurement parameters in plasma. In stage 1, only one parameter is altered which, moreover, is not routinely assessed in clinical analyzes; in stage 2, a parameter is potentially altered that is analyzed more routinely and in the following stages even more values are altered.
[0126]
[0127] Example 3. Reference assessment of hemolysis.
[0128]
[0129] To validate the degraded scale elaborated according to example 2, a spectrophotometry methodology was used since, although it is not the most discriminative technique of those currently existing, in general, it is considered sufficient for the detection of hemolysis in isolated blood samples.
[0130]
[0131] A NanoDrop ™ 2000 Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, United States of America) was used, with a broad ultraviolet-visible spectrum (190-840 nm) and requiring microvolumes of 0.5 to 2 pl of initial sample. Using this spectrophotometer, highly concentrated samples can be measured without the need to dilute them beforehand.
[0132]
[0133] In this example, in each sample, the absorbance of deoxyhemoglobin across the spectrum was measured through 2 pl of plasma. The plasma of each sample was obtained as indicated in Example 4. The NanoDrop ™ 2000 Spectrophotometer was calibrated with 2 pl of distilled water, the measurement was performed and, after obtaining the adimensional absorbance unit in the NanoDrop 2000 / 2000c software 1.6.198 Thermo Fisher Scientific Inc., was cleaned with disposable tissues. Next, 2 pl of plasma were taken from an isolated blood sample and analyzed, repeating the process at least 3 times, cleaning with a handkerchief between each measurement. Between the third measurement of a sample and the first measurement of the following sample, the area of the NanoDrop ™ 2000 Spectrophotometer that contacts the sample was cleaned with 2 pl of distilled water and 1 or 2 measurements were made to confirm that there was drag of the analysis of a sample with the following one.
[0134]
[0135] Example 4. Procedure for validation of the degraded scale.
[0136]
[0137] In each visual observation (test and retest) there were two observers. The two observers of the test of a specific batch of samples were the same as the two observers of the retest of said batch. The observers were established based on:
[0138]
[0139] - Title,
[0140]
[0141] - experience in hemolysis inspection and laboratory sample processing,
[0142] - availability of collaboration in the laboratory at three times each day.
[0143]
[0144] The observers received a previous 10-minute training to conduct the evaluations. Subsequently, they were allowed to take a maximum of one minute to evaluate each sample.
[0145]
[0146] From each sample isolated from blood, blood plasma was obtained. For this, the samples were collected in EDTA tubes (ethylenediaminetetraacetic acid) since it is the most used as an anticoagulant because it interferes with very few blood determinations. Plasma was obtained by centrifuging each sample at 3400 rpm for 10 minutes at 4 ° C, within a maximum of two hours after sampling. The plasma content was transferred to the largest possible number of 1.4 ml tubes (Wilmut, W-2DPH 1.40 ml, Nirco, SL, Barcelona, Spain). The first tube was standardized to a minimum volume of 150 pl and was identified with a V in the upper part of the tube, where there was no plasma to not interfere with color visualization. All tubes with plasma content were reserved by storing them at -80 ° C. Subsequently thawed samples that were labeled by slow thawing with orbital shaker. Immediately before the spectrophotometry analysis, the plasma-containing tubes were vortexed.
[0147] Each observer was asked to visually inspect the color tone of the plasma of a tube from each sample isolated from blood, to evaluate and record the stage of the degraded scale with which the plasma tone contained in the tube coincided, according to its criteria . Their agreement and discordance were checked according to the stage corresponding to the absorbance measured for the plasma of that sample.
[0148] A traceability between numbers and letters was developed. The first observation of the plasma tubes corresponded to numbers and the second to letters. Plasma tubes were ordered from left to right in ascending numerical order and alphabetically, respectively. The traceability record was made by a person responsible for the coordination of field work, which had unique access. With the identification of the second alphabetic sequence blinding was performed to the observers. The absorbance measurement was blind and was performed in a laboratory other than the laboratory in which the visual evaluation was performed.
[0149] A minimum number of samples of 6 and maximum of 16 per batch was considered adequate and the procedure was performed twice per sequence in each batch of 1.4 ml tubes:
[0150] - test: the centrifuged tube was collected and 150 ql of the total plasma was transferred to a 1.4 ml tube. The sample contained in the tube was visually evaluated and subsequently frozen;
[0151] - re-test: at 24-48 hours post-freezing, the plasma-containing tubes used in the test were thawed and those samples were visually evaluated again; subsequently, they were analyzed by spectrophotometer, as indicated in example 3, subsequently freezing the tube.
[0152] To perform the visual evaluation artificial light was used.
[0153] The person responsible for the coordination monitored the non-influence among observers preventing them from coming together in the same laboratory. Each evaluation record was kept, immediately after completion, in an envelope with limited access only to the coordinator and locked away.
[0154] 4.1. Sample size.
[0155] A unilateral sample calculation of the proportion observed with respect to a reference was carried out, with an alpha error of 5% and a power of 80%, unilateral test. The reference proportion was 46.6% based on a study in which, of 15 samples identified with the presence of hemolysis through spectrophotometry, 8 of them were not detected visually and 7 could be detected through the human eye (Shash , JS et al. PLoS ONE 2016; 11 (4) 1-12). The objective was to reach a concordance of at least 85%, justified by being a certainty value considered sufficiently satisfactory; what was considered optimal to detect the intensity of hemolysis in each stage.
[0156] H0: The concordance of hemolysis intensity through visual stages is not optimal <0.70.
[0157] H1: The concordance of hemolysis intensity through the visual stages is optimal>0.85; at least 0.85.
[0158] Therefore, the minimum difference to be detected was obtained through the objective of 85% - 46.6%, that is, 38.4%. Finally, it was concluded that at least 9 samples were needed or, what is the same, 10 blood samples per stage, with an expected proportion of losses of 10% due, essentially, to samples with insufficient blood content for inspection. Since the scale consisted of 7 stages, in total, 63 isolated blood samples per scale were needed, or 70 blood samples per scale, including losses.
[0159]
[0160] 4.2. Statistical analysis.
[0161]
[0162] The parameters of reliability, validity and feasibility were evaluated.
[0163]
[0164] Spearman's correlation coefficient was used to observe the trend and strength of relationships between variables; the Kappa de Cohen index to know the concordances and disagreements of the stadiums; the Kaiser-Meyer-OIkin (KMO) and Bartlett's sphericity test (chi-square model); the intraclass correlation coefficient for the spectrophotometry reliability in all repeated absorbance measurements.
[0165]
[0166] A non-parametric distribution was detected through the Kolmogorov-Smirnov normality test (p-value <0.05). Therefore, the Kruskal-Wallis statistical test was used to know the heterocedasticity between the stages of the scale; and a descriptive statistic to assess the feasibility.
[0167]
[0168] The analysis was performed by protocol compliance, the samples necessary to complete the sample size of each stage. That is, those plasma samples that the observers considered were not optimal for visual detection due to potential lipemia, were excluded.
[0169]
[0170] The statistical program SPSS version 23 and the Microsoft Excel XLSTATA program were used to address the validity of predictive criteria.
[0171]
[0172] Ethical and quality aspects
[0173]
[0174] The subjects signed the informed consent corresponding to a clinical trial in which they participated. Of the remaining blood to that required by the test, part was used for the elaboration and testing of the scale. However, no traceability was collected in the identification of blood samples for validation, they were identified in chronological order of obtaining. In addition, no additional blood sample was extracted, the plasma was obtained from the amount of blood remaining from the sample justified by the clinical trial for which the subjects provided their signed consent, and were destroyed as appropriate, so it was not considered Additional specific consent required.
[0175]
[0176] The methodology used to carry out the validation of the scale is supported by the guide of STARD diagnostic precision studies published in 2015 (Bossuyt, P.M. et al. BMJ 2015; 351: h5527).
[0177]
[0178] 4.3. Theory / calculation
[0179]
[0180] At 414 nanometers (nm), where the maximum intensity of free plasma hemoglobin is generally found, it is a specific measurement point at which the bilirubin and lipemia absorbance curves overlap; between 400 nm and 540 nm for the detection of jaundice, the maximum expression is evidenced at 460 nm, and between 300 nm and 750 nm for lipemia, without maximum peak but with optimum absorbance at 300 nm. In addition, there are currently some guidelines for the assessment of cardiovascular risk with certain tests performed blood conditions not necessarily fasting (such as the measurement of triglycerides and glycosylated hemoglobin), so it is considered that the lipemia correction adjustment method that Appierto, V. et al. propose in Bioanalysis. 2014; 6: 1215-1226: (A414-A385) + 0.16xA385.
[0181] In each measurement, the entire range from 0 nm to 750 nm of each sample was obtained.
[0182] For the elaboration and validation of the scale, three measurements were made corresponding to each plasma sample, the absorbance at 750 nm was calculated to perform a basal correction in each sample. Also, the absorbance at 414 nm and at 385 nm was calculated. Subsequently, the calculation was made according to the formula of Appierto, V et al. (2014).
[0183] In cases where the 3 absorbance measurements were very different, up to a maximum of 6 additional measurements were made. That is, at least 3 and maximum 9 measurements were made from the same plasma sample. Of the total measurements, the arithmetic mean was performed with those 3 most similar measurements, eliminating the most extreme values.
[0184] As a result, three corrected absorbance values were obtained. The arithmetic mean of these three corrected measurements that resulted in a single final value corresponding to a sample was calculated.
[0185] Number of samples
[0186] A total of 80 blood samples were included, in total, from 64 subjects. Each stage was validated by a certain number of samples: stage 1 validated by 14 samples, stage 2 validated by 16 samples, stage 3 validated by 10 samples, stage 4 validated by 10 samples, stage 5 validated by 9 samples, stage 6 by 9 samples and stage 7 for 12 samples.
[0187] Interobserver Reliability
[0188] A Cohen Kappa index of 0.491 was obtained in the test and 0.270 in the retest. It is considered a moderate and acceptable agreement, respectively, according to Landis and Koch (Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005 May; 37 (5): 360-3).
[0189] Intraobserver reliability
[0190] On the other hand, a Cohen Kappa index of 0.474 was obtained in the test and retest of the first observer. Kappa de Cohen's index of 0.499 in the test and re-test of the second observer. A moderate agreement is considered in both observers according to Landis and Koch.
[0191] Instrument reliability
[0192] The intraclass correlation coefficient (ICC) of the repeated absorbance measurements of each sample was determined to represent the stability of the measurements of the reference instrument. In the retest, an ICC of 0.995 in a 95% confidence interval (CI) (0.992-0.996) was obtained.
[0193] Reliability of internal consistency
[0194] Heterocedasticity between the stages that make the scale is explained, according to the magnitude of hemolysis that each stage represents. It is observed in table 3 and in figure 3, through the Kruskal-Wallis test (p = 0.000); each stage contains a different variance of data, so that the lower stages are formed by smaller variances and, at As the magnitude of hemolysis increases, the variance of the data that make up the successive stages increases according to the close clinical relevance between stages 1 and 2, which dissipates as the sample becomes more hemolyzed.
[0195]
[0196]
[0197]
[0198] Table 3. Kruskal-Wallis test for the seven stages of the hemolysis scale.
[0199] In combination, table 4 represents a significant increase in absorbance throughout the stages; through a correlation of Spearman:
[0200]
[0201]
[0202]
[0203] a The null hypothesis is not assumed.
[0204] b Use of the asymptotic standard error that assumes the null hypothesis.
[0205] c It is based on normal approximation.
[0206] Table 4. Relationship between arithmetic mean of absorbances and stages. Spearman correlation.
[0207] In the same way, the standard deviations of the plasma samples used for the validation of each stage that were the following are shown:
[0208] Stage 1: 0.018; stage 2: 0.009; stage 3: 0.013; stage 4: 0.015; stage 5: 0.055; stage 6: 0.036; and stage 7: 0.277.
[0209] As a consequence of the pairs of stages of possible combinations for their comparisons, an alpha adjustment was carried out through the Bonferroni test. Since the combinations in total were 21, the fixed alpha was raised from 0.05 to 21. A significant alpha was obtained <0.002 and an interval and confidence of 99.8%.
[0210] Appearance validity
[0211] The magnitude and clinical relevance of hemolysis represented is supported by underlying theory in a panel of experts (Appierto, V. et al. Bioanalysis. 2014; 6: 1215-1226; Saldaña, IM An Fac Meó 2015; 76 (4): 377 -384; Plumhoff EA, et al. Mayo Medical Laboratories. Communiqué.
[0212] 2008; 33 (12): 1-8).
[0213] Content Validity
[0214] The adequacy of the absorbances of the plasma samples obtained in the experimental field work was evaluated to reflect the full spectrum of the hemolysis absorbance magnitude, as set out in Table 5, Kaiser-Meyer-OIkin (KMO )> 0.70.
[0215]
[0216] In the same way, in Table 5, it was evaluated that the variables of arithmetic mean absorbance and the stage variable have a significant correlation between them to represent the hemolysis dimension (p-value = 0.000). Therefore, the dimension was correctly represented and there were no more dimensions, not foreseen, responsible for the magnitude of hemolysis in the plasma samples of the field work.
[0217]
[0218]
[0219]
[0220] Table 5. KMO and Bartlett tests of the stadiums according to arithmetic means. Content validity.
[0221]
[0222] Validity of criteria. Global concurrent validity
[0223]
[0224] The concordance of the stages of the scale were evaluated globally. That is, concordance of stages assigned by observers in the test and retest were evaluated in reference to the stage assigned by the arithmetic mean of the absorbance measurements of each plasma sample. Table 6 shows an overall agreement> of 70% in the test.
[0225]
[0226]
[0227]
[0228] Table 6. Global concordances and disagreements of the stages according to arithmetic mean absorbance depending on the moments of the test and retest.
[0229]
[0230] Absolute intrastate concordance of the scale in the retest: stage 1 of 100%, stage 2 of 100%, stage 3 of 90%, stage 4 of 60%, stage 5 of 33.3%, stage 6 of 11.1 % and stage 7 of 63.6%. In the disagreements found, a Spearman Rho was obtained between the visual stage of the observers and that produced by absorbances of 90%; the correlation was significant at the 0.01 level (unilateral).
[0231]
[0232] Predictive validity
[0233]
[0234] It is observed in table 6 that the test does not reach a satisfactory parameter, evaluating the plasma samples within 48 hours before being analyzed. However, in the re-test, in which a satisfactory parameter is found, it is also predictive, since it is evaluated before analyzing absorbances, but in a short period of time.
[0235]
[0236] Therefore, the global scale criterion measurements in the retest are shown in Table 7, that is, from stages 2 to 7 with respect to stage 1. The concordance set forth refers to correct absolute classifications with implicit clinical relevance.
[0237] The prevalence of stage 1, which was 0.188, was calculated.
[0238]
[0239]
[0240]
[0241] Table 7. Validity measurements of global criteria in the joint stages of the scale.
[0242]
[0243] Stage 2: Concordance of 0.886 in a 95% confidence interval (CI) (0.780-0.780), discrepancies of 0.114 95% CI (0.009-0.220), sensitivity of 0.80 in a 95% CI (0.577-0.923) , specify 1.00 in a 95% CI (0.757-1.00), false positive rate of 0.00, false negative rate of 0.200 in a 95% CI (0.040-0.360). Prevalence of 0.571 in a 95% CI (0.407 0.735), Positive Predictive Value (PPV) of 1.00 in a 95% CI (1.00-1.00), Negative Predictive Value (NPV) of 0.952 in a 95 CI % (0.857-1.00). Negative likelihood ratio (LR-) of 0.20 in a 95% CI (0.083-0.481). Relative risk (RR) of 4,750 in a 95% CI (2,112-10,681).
[0244] Stage 3: Concordance of 0.960 in 95% CI (0.883-1.00), mismatches of 0.040 95% CI (0.000-0.117), sensitivity of 0.90 in a 95% CI (0.571-1,000), specificity of 1.00 in a 95% CI (0.757-1.00), a false positive rate of 0.00, a false negative rate of 0.100 in a 95% CI (0.000-0.257). Prevalence of 0.400 in a 95% CI (0.208-0.592), PPV of 1.00 in a 95% CI (1.00-1.00), NPV of 0.986 in a 95% CI (0.928-1.00). LR- of 0.100 in a 95% CI (0.016 0.642), RR of 16,000 in a 95% CI (3,479-73,583).
[0245]
[0246] Stage 4: Concordance of 0.600 in 95% CI (0.438-0.762), mismatches of 0.400 95% CI (0.238-0.562), sensitivity of 0.300 in 95% CI (0.145-0.522), specificity of 1,000 in 95% CI (0.757-1.00), false positive rate of 0.000, false negative rate of 0.700 in a 95% CI (0.517-0.883). Prevalence of 0.571 in a 95% CI (0.407-0.735), PPV of 1.00 in a 95% CI (1,000-1,000), NPV of 0.909 in a 95% CI (0.804-1.00). LR- of 0.700 in a 95% CI (0.525-0.933), RR of 2.071 in a 95% CI (1.435-2.990).
[0247]
[0248] Stage 5: Concordance of 0.947 in 95% CI (0.847-1,000), mismatches of 0.053 95% CI (0.000-0.153), sensitivity of 0.750 in a 95% CI (0.290-0.960), specificity of 1,000 in a 95% CI (0.757-1.00), false positive rate of 0.000, false negative rate of 0.250 in a 95% CI (0.000-0.550). Prevalence of 0.211 in a 95% CI (0.027-0.394), PPV of 1,000 in a 95% CI (1.00-1.00), NPV of 0.969 in a 95% CI (0.884-1,000), LR- of 0.250 in a 95% CI (0.046-1.365), RR of 16,000 in a 95% CI (3,479-73,583).
[0249]
[0250] Stage 6: Concordance of 0.842 in 95% CI (0.678-1,000), discrepancies of 0.158 95% CI (0.000-0.322), sensitivity of 0.250 in a 95% CI (0.040-0.710), specificity of 1,000 in a 95% CI (0.757-1.00), false positive rate of 0.000, false negative rate of 0.750 in a 95% CI (0.450-1,000). Prevalence of 0.211 in a 95% CI (0.027-0.394), PPV of 1,000 in a 95% CI (1,000-1,000), NPV of 0.913 in a 95% CI (0.782-1,000), LR- of 0.250 in a 95% CI % (0.046-1.365), RR of 6,000 in a 95% CI (2,336-15,411).
[0251] Stage 7: Concordance of 1,000 in 95% CI (1,000-1,000), mismatches of 0.000 95% CI (0.000-0,000), sensitivity of 1,000 in a 95% CI (0.590-1,000), specificity of 1,000 in a 95% CI (0.757-1,000), false positive rate of 0.000, false negative rate of 0.000 in a 95% CI (0.000-0,000). Prevalence of 0.318 in a 95% CI (0.124-0.513), VPP of 1,000 in a 95% CI (1,000-1,000), NPV of 1,000 in a 95% CI (1,000-1,000), LR- of 0.000 in a 95 CI % (0.000-0,000). The calculation of RR was not possible.
[0252]
[0253] Construct validity
[0254]
[0255] A proportion of 0.713 in a 95% confidence interval (0.611-0.814) of concordance of the scale at a global level is considered to be a sufficiently satisfactory parameter despite not rejecting the null hypothesis. In addition, the VPPs of the stages of the scale exceed 85%; being a more practical measurement for the objective designed in the practical clinical application.
[0256]
[0257] Feasibility
[0258]
[0259] The observers dedicated a visual inspection time in each sample represented in arithmetic mean (variance) of 0.200 (± 0.003) minutes, minimum of 0.12 minutes and maximum 0.33 minutes in the retest (number of samples = 80) .
[0260]
[0261] The observers required a previous training of the use of the 10-minute scale.
[0262]
[0263] 4.4. Interpretation of results
[0264]
[0265] The overall reliability among the observers is considered acceptable, and the moderate intraobserver reliability, according to Landis and Koch, in the re-test of the scale, which suggests a slight variation of judgment among the observers, which may be due to an absence of unification of criteria.
[0266]
[0267] Repeated absorbance measurements in samples represent stability based on the intraclass correlation index represented, approximately 99%, of both the plasma content to be measured and the spectrophotometer measuring instrument.
[0268]
[0269] Significant heterocedasticity between stages is evidenced through Kruskal-Wallis (p = 0.000). In such a way that the greater the stage number, the greater the variance of the absorbances of the included plasma samples. It agrees with the clinical relevance whose majority of parameters measured in plasma begin to trigger cumulative alterations in stage 2 and successive, with a very narrow variance between stages 1 and 2, so the scale is consistent with the representation of a sample of plasma in a specific stage and not in several; Therefore it is discriminative. Additionally, a strong relationship is observed because as the value of the stage increases from 1 to 7, the value of absorbances increases. Therefore, the scale is considered to be consistent with the theoretical measurement construct, its magnitudes and clinical relevance, since the heterocedasticity and the strong correlation between absorbances and an increase in the number of stages are expected.
[0270] Plasma samples included in the field work of the scale cover a sufficient spectrum to test this scale (KMO = 0.71). That is, it is based on a cluster of possible cases that represent the majority of expected cases when applied in another environment; in whose case it is possible to identify each case and expose it through the classification from 1 to 7. In the same way, the unidimensionality of the scale elaborated by the variables of stages and arithmetic mean of absorbances is observed, which shows the correct approach to the hemolysis construct and its magnitudes in a single dimension.
[0271] Regarding the validity of the criterion, the overall concordance ratio is considered satisfactory. These agreements are distributed in a non-proportional manner between their stadiums, but, with the exception of stage 4, all others reach a satisfactory value (greater than or equal to 70%). Stage 4, despite not reaching a satisfactory result, not only results in a close value, but the value of 0.70 is among the possible concordance values collected in the interval of stage 4 in the sample studied with a probability of success of 95%. In addition, stage 4 maintains a strong relationship between visual evaluation and absorbance analysis, suggesting a robust orientation of potentially altered parameters when reaching the hemolysis intensity corresponding to stage 4. All stages are useful for the detection of absence. of hemolysis with clinical impact; 100% specificity and 0% false positives. Sensitivity> 70% except stage 4 and 6. The false negative rate is small, except in stages 4 and 6. All stages predict the magnitude of corresponding hemolysis, adequately (PPV> 70%). Despite the low prediction of absence of hemolysis in plasma samples globally (NPV <70%), probably influenced by the low prevalence, in stages 2 to 7 included it is satisfactory (NPV> 70%). The likelihood ratio that a hemolyzed sample is not identified as such and its magnitude is low, except in stage 4, which has not found a discriminative characteristic. In addition, as the stages increase, the probability of screening in the identification of hemolyzed versus unhemolyzed samples is greater, although the increase is not linear.
[0272]
[0273] In the validity of the construct, concordances of 71.3% are obtained in a 95% confidence interval of (61.1% -81.4%). 85% is not preset between their values from a point of view of The global scale In each of the stadiums, all reach a construct validity, except stage 4; likely responsible for not reaching the validity of global construct. For this reason, it is not possible to reject the null hypothesis, it remains.
[0274] All the correct classifications contain at least 70% between their 95% confidence interval values; which corresponds to a classification considered theoretically as adequate.
[0275]
[0276] The scale reflects a criterion validity, not that construct, for the sample size addressed; It could be due to insufficient capacity in field work. However, it is closely related to the upper limit of the confidence interval of such calculated value.
[0277] Limitations
[0278]
[0279] Covariance between stages is not calculated, since all stages are delimited by the immediately consecutive absorbance number; So it does not apply.
[0280]
[0281] It is not possible to know the positive likelihood ratio due to the presence of complete specificity in the field work.
[0282]
[0283] It is not possible to know the validity of the construct through a hypothesis test because it is a sample and, therefore, the p-value does not apply.
[0284]
[0285] It is not possible to calculate a divergent validity or reliability of non-bioequivalence between the scales, since it does not apply.
[0286]
[0287] Nor can the discriminative validity in lipemia and bilirubinemia be known, because possible interferences have been eliminated through analytical tests for bilirubin control in normal range and fasting samples, preferably, in addition to applying the correction factor of Lipemia
[0288] conclusion
[0289]
[0290] In the detection of visual hemolysis, with bilirubin in the range of normality controlled and corrected in lipemia, the degraded hemolysis intensity scale is a useful tool that reflects the reality of the underlying theoretical construct with an impact of sufficiently satisfactory clinical benefits.

权利要求:
Claims (6)
[1]
1. Procedure for the visual detection of the degree of aptitude of an isolated blood sample for validation in clinical analysis based on the degree of hemolysis of the sample, which includes:
- obtaining the plasma from the sample,
- the comparison of the plasma color of the sample with a degraded color scale that includes the entire range of color intensities from 55 ° to 00 ° and from 00 ° to 351 °, with 00 ° being the red color in the chromatic circle of a double cone and in which said range of intensities is divided into 7 intervals of equal size that correspond to the following stages: stage 1: 55 ° -44 °, stage 2: 43 ° -38 °; stage 3: 37 ° -26 °; stage 4: 25 ° -16 °; stage 5: 15 ° -07 °; stage 6: 06 ° -01 °; stage 7: 00 ° -351 °, whose harmonization in saturation and brightness, respectively, are: stage 1: 35% - 44%, 99% - 89%; stage 2: 47% -50%, 90% -90%; stage 3: 50% -60%, 93% - 89%; stage 4: 68% -80%, 95% - 80%; stage 5: 71% -81%, 91% - 78%; stage 6: 68% -83%, 80% - 70%; stage 7: 82% -88%, 70% - 55%,
- the assignment of the sample to one of the 7 stages of the degraded scale.
[2]
2. The method according to claim 1 wherein the degraded color scale occupies an area 210 mm high by 297 mm long, each stage corresponding to a size of 105 mm high by 41 mm wide, the set of Colors of the scale occupies 105 mm high by 287 long, with a margin of 52.5 mm at the top as at the bottom and 5 mm at the right as left in which the color is matt white.
[3]
3. Method according to any of the preceding claims wherein the device where the degraded color scale is included is made of a material comprised in the following group: paper, cardboard, cardboard-pen, plastic and / or metal.
[4]
4. Degraded color scale for visual detection of the degree of suitability of an isolated blood sample for validation in clinical analysis based on the degree of hemolysis of the sample, according to the procedure defined in claims 1-3, which includes all the range of color intensities from 55 ° to 00 ° and from 00 ° to 351 °, with 00 ° being the red color in the color wheel and in which said range of intensities is divided into 7 equal intervals size corresponding to the following stages: stage 1: 55 ° -44 °, stage 2: 43 ° -38 °; stage 3: 37 ° -26 °; stage 4: 25 ° -16 °; stage 5: 15 ° -07 °; stage 6: 06 ° -01 °; stage 7: 00 ° -351 °. Whose harmonization in saturation, and brightness respectfully is: stage 1: 35% - 44%, 99% - 89%; stage 2: 47% -50%, 90% -90%; stage 3: 50% -60%, 93% - 89%; stage 4: 68% -80%, 95% - 80%; stage 5: 71% -81%, 91% - 78%; stage 6: 68% -83%, 80% - 70%; stage 7: 82% -88%, 70% - 55%.
[5]
5. Device for visual detection of the degree of suitability of an isolated blood sample for validation in clinical analysis based on the degree of hemolysis of the sample that includes the color scale defined in claim 4, wherein the degraded scale It occupies an area of 210 mm high by 297 mm long, each stage corresponding to a size of 105 mm high by 41 mm wide, the set of colors of the scale occupies 105 mm high by 287 long, with a margin of 52.5 mm at the top as at the bottom and 5 mm at the right as left in which the color is matt white.
[6]
6. Device according to claim 5 made of a material selected from the group: paper, cardboard, cardboard-pen, plastic and / or metal.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2845348T3|2021-07-26|Short and Long Sample Detection Systems and Procedures

---

US6562625B2|2003-05-13|Distinguishing test types through spectral analysis

---

WO2015038717A1|2015-03-19|System for diagnostic testing of liquid samples

---

US10823745B2|2020-11-03|Blood test kit and blood analysis method

---

US20190212345A1|2019-07-11|Kits and methods for determining physiologic level| and/or range| of hemoglobin and/or disease state

---

US9128168B2|2015-09-08|Method of determing excretion of sodium and other analytes

---

US20070276260A1|2007-11-29|Method For Measuring The Vessel Diameter Of Optically Accessible Blood Vessels

---

ES2733148B2|2020-10-07|Procedure and device for the visual detection of the degree of suitability of an isolated blood sample for its validation in clinical analyzes

---

US9045792B2|2015-06-02|In vitro method for analyzing a comparison of an indicative numberic value to a predetermined threshold so as to assess a likelihood of risk or presence of organ failure

---

CN104698160B|2016-09-28|A kind of test kit for assessing male&#39;s twenty-four-hour urine sodium value

---

ES2279556T3|2007-08-16|PROCEDURE TO IMPROVE THE PRECISION OF THE SEMICUANTITATIVE DETERMINATION OF ANALYTE IN FLUID SAMPLES.

---

CN104819981A|2015-08-05|Urine component measuring instrument

---

JP6762703B2|2020-09-30|Method for discriminating tumor site, tumor site discriminating device

---

CN106662573B|2019-10-11|For determining the container of urinary precipitation in analyte and/or chemico-physical parameter and determining urine in urine；And the method for using the container carrying out full urinalysis

---

Fulks et al.2012|Urine protein/creatinine ratio as a mortality risk predictor in non-diabetics with normal renal function

---

CN108133754B|2019-03-12|The forecasting system of bleeding risk after a kind of thrombolysis

---

WO2019089768A1|2019-05-09|Low resource device and system for measurement of bilirubin levels

---

JP2022514833A|2022-02-16|Method for measuring hematocrit value in whole blood sample

---

Niculescu et al.2020|Portable Biochemistry Analyzer Based on Image Acquisition Algorithm

---

RU2362479C1|2009-07-27|Estimate method of scleral icterus symptom

---

US9179839B2|2015-11-10|Method for determining at least one diagnosis or risk assessment parameter related to AMD

---

US20200209144A1|2020-07-02|Plasmonic sensors and methods for the detection of corneal injury

---

Hennig et al.2014|Dual-wavelength excitation to reduce background fluorescence for fluorescence spectroscopic quantitation of erythrocyte zinc protoporphyrin-IX and protoporphyrin-IX from whole blood and oral mucosa

---

US20110118141A1|2011-05-19|Disease Specific Diagnostic Aid

---

JP2018179565A|2018-11-15|Risk estimation method and system of aged related macular degeneration disease

同族专利:

---

公开号 | 公开日

---

WO2020193839A3|2020-12-10|

---

WO2020193839A2|2020-10-01|

---

ES2733148B2|2020-10-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

法律状态:
2019-11-27| BA2A| Patent application published|Ref document number: 2733148 Country of ref document: ES Kind code of ref document: A1 Effective date: 20191127 |

---

2020-10-07| FG2A| Definitive protection|Ref document number: 2733148 Country of ref document: ES Kind code of ref document: B2 Effective date: 20201007 |

优先权:

---

申请号 | 申请日 | 专利标题

---

ES201900050A|ES2733148B2|2019-03-28|2019-03-28|Procedure and device for the visual detection of the degree of suitability of an isolated blood sample for its validation in clinical analyzes|ES201900050A| ES2733148B2|2019-03-28|2019-03-28|Procedure and device for the visual detection of the degree of suitability of an isolated blood sample for its validation in clinical analyzes|

---

PCT/ES2020/070344| WO2020193839A2|2019-03-28|2020-05-26|Method and device for the visual detection of the degree of suitability of a sample isolated from blood for its validation in clinical analyses|